IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

Nanoparticles as carriers in Cancer therapy

Yash R. Tatipamul[1] , Amar B. Matnali[2] , Vaishnavi S. Patole[3]

[1,2,3]Department of Pharmaceutics, Lokmangal College of Pharmacy, Wadala, Solapur, India.

Abstract

Around the world, cancer is becoming the leading cause of death in many communities. With over 25% of all deaths, cancer is the second most common cause of death in the United States. Approximately 500,000 people die and one million cases are diagnosed annually.(1) First of all the scientific fields of biology, chemistry, physics, engineering, and medicine are all combined in nanotechnology. The creation of multifunctional nanoparticles having the ability to distribute and release drugs in a regulated manner, target cancer cells specifically, and detect cancer cells with high sensitivity and specificity.(2) A variety of potentially effective options for creating customised drugs for cancer detection and treatment are offered by nanoparticle platforms. There are two methods for targeting nanoparticles: passive targeting and active targeting. In the tumour microenvironment, passive targeting enables effective localization of nanoparticles. Nanoparticles are actively absorbed by cancer cells when they are actively targeted. Treatment options consist of radiation, chemotherapy, and surgery exclusively. Chemotherapy agents can be specifically targeted with a nanoparticle-based medication delivery system. With nanotechnology developing at a rapid pace, better cancer therapy approaches are possible thanks to the development of nanomedicine agents. (4) This review paper demonstrates the significance of nanocarriers, their kinds, and targeted medication delivery using polymer-based drug carriers.

Keywords – Cancer, Nonoparticles, Targeted drug delivery System, Polymer based drug carriers

1. Introduction

Uncontrollably growing and spreading cells characterise cancer. (5) Worldwide, cancer is a major public health concern. Over the next few decades, cancer incidence is expected to rise due to global population trends, with over 20 million additional cases of cancer annually predicted by 2025. In 2012, 8.2 million people died from cancer, and 14.1 million new cases were diagnosed, according to GLOBOCAN data. (6) The theory of log kill is how cancer cells function.

1.1 Properties of Cancer cells

1. Rapid cell division rate
2. In Vasiueness
3. Metastasize
4. Aquired heridity
5. Abnormal cell metabolism

1.2 Causes

There are many causes which may cause Cancer in different body parts like mainly due to :-

- Tobacco, whereas 10% of deaths are related to obesity, poor diet, inactivity, and excessive alcohol consumption. Ionising radiation exposure, sickness, and exposure to contaminants in the environment are further contributing factors. (6)
- Physical carcinogens, such as ultraviolet and ionising radiation.
- Chemical carcinogens, such as asbestos; arsenic-containing drinking water components; and aflatoxin-containing food.
- Biological carcinogens, such as infections caused by bacteria, viruses, and parasites. (8)
- Among patients with advanced cancer, anorexia and cachexia are important causes of morbidity and mortality.
- Cachexia affects 50% of cancer patients who are actively undergoing treatment and 80% of patients who have passed away. It is more prevalent in young people and the elderly and becomes more obvious as the disease advances. (9)

1.3 Symptoms

Patients with cancer experience multiple symtoms including :-

- Pain
- Dyspnoea
- Fatigue
- Depression
- Cognitive impairment [10]

1.4 Pathophysiology



2. Treatment of cancer :-

Several factors, such as the disease's kind and stage, the patient's general health, and their preferences, influence the choice of cancer treatment. There are several therapeutic approaches that can be used, including immunotherapy, chemotherapy, radiation therapy, targeted therapy, and surgery.[11] The use of nanotechnology in cancer treatment creates new possibilities. The development of functionalized patches for tailored treatment carries the implicit promise of reducing systemic toxicity. Additionally, due to their ability to circumvent the medication efflux medium linked to this particularity, they provide a vital means of preventing multidrug resistance.[13] Submicronic (1m) colloidal systems, or nanoparticles, are typically made of polymers (biodegradable or not). However, this is not always the case. Different methods for preparing the nanoparticles can result in different types of nanospheres or nanocapsules.[12] In the multidisciplinary discipline of nanotechnology, concepts from engineering, biology, chemistry, and pharmaceuticals are used to build and create bitsy bias. In its most restrictive sense, nanotechnology describes structures that have at least one dimension and range in size from 1 to 100 nm.[14] New approaches to treating cancer are provided by the use of nanoparticles in drug delivery. Many organic and inorganic accessories, as well as a variety of nanoparticle delivery systems, have been developed for the treatment of cancer within the past 20 years. [15] The creation of intelligent targeted nanoparticles (NPs) with the capacity to continuously deliver particulars to cancer cells may result in improved efficacy and reduced toxicity when treating primary and advanced metastatic tumours.[16]

3. Mechanism of drug targeting

The major obstacles in the medicine delivery by remedial agents are their nonspecific, resistance, and systemic toxin. Thus, targeting the cells widely and Specifically by the medicine are the salient features of Nano based medicine deliverysystem.There are two different approaches for targeting the cells by Nanocarriers unresistant Targeting and active targeting. :-

3.1 Passive cancer targeting-

Through the facilitation of the accumulation of nanoparticle delivery systems such as polymeric nanoparticles, liposomes, micellar systems, and polymeric-medication conjugates, the physiological features of the tumour play a significant role in passive targeting.[42] Because unresistant prolixity is satisfied by prolixity-mediated transport, nanoparticle size is important for passive targeting. The body's reaction to

an illness or inflammation causes it to travel to the intended location. Based on the nanoparticles' size, shape, and surface charge. Anatomical barriers or physiological state may have an impact on passive targeting. It modifies the body's biodistribution of the medication.

3.2 Active cancer targeted-

Utilising the existence of certain halves, active cancer targeting enhances the distribution of nanoparticles to the tumour site . Drug will be released at the intended location once the carrier reaches it. To deliver nanoparticles to the target tissue, they rely on affinity ligands, ligand receptors, antigen-antibody reactions, or other types of chemical reactions. Increases cellular uptake by concentrating on specific cells. The two most crucial factors in assessing the efficacy of active targeting are targeting specificity and delivery capability. The ability to deliver what needs to be delivered The structure and makeup of a nanoparticle directly affect its capability.[45]

4. Targeted medicine delivery of nanoparticles

The idea of a targeted treatment first emerged with the discovery of antibodies in the late 1970s, but the use of immunoliposomes to create tailored nanoparticles emerged more recently. Site-specific medication delivery is another name for targeted drug delivery. It is described as a formulation and device that, by regulating the rate, duration, and location of drug release in the body, introduces a sample of therapeutic chemicals at the intended site safely and effectively. The interaction of drug molecules with cell membrane-related biological activities at receptor sites determines a drug's therapeutic response, and this interaction is concentration dependent. It is evident that the majority of diseases treated with cytotoxic drugs require not only accurate and regulated drug delivery, but also a quantitatively defined, characterised, and precise delivery pattern. To get around the drawbacks of the traditional dosage form and increase the therapeutic efficiency of the medication, a system of this kind has to be developed.[28] Because of their unique physical, chemical, and natural properties, nanoparticle-based medicine-delivery systems have significantly improved the point-specific release of medications, particularly chemotherapeutic drugs.[17] Nanoparticles, nanospheres, or nanocapsules can be designed to hold distinct packages and release properties for the elegant delivery or encapsulation of the therapeutic ingredient, depending on the medicine system.[18]

Ideal Properties of TDDS

- Both in vivo and in vitro, nontoxic, biocompatible, and physiochemically stable.
- Limit the distribution of drugs to specific cells, tissues, or organs.
- Controllable and predictable rate of medication release.
- Very little drug leaking while in transportation.
- The carrier that is employed must to be biodegradable or easily removed from the body.
- Its preparation should be reproducible, inexpensive, and easy to somewhat basic.

5. Polymer based drug carriers :-

Polymer-based drug delivery systems Drugs with nanocarriers have been created to decrease harmful side effects and increase therapeutic efficacy. Nanocarriers offer improved drug localization and cellular absorption along with continuous, direct, and controlled drug release to pathogenic cells.[23] The use of biodegradable polymer NPs in the treatment of cancer has been thoroughly studied. The most often used polymers for nanoparticles have been poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and their copolymers, poly(lactide-co-glycolide) (PLGA). The intrinsic resorbability and biocompatibility of these polymers are widely recognised. It is also possible to modify the rate of declination and, thus, the rate of drug release by changing the rate of PLA, which has increased hydrophobicity, to PGA, which has increased hydrophilicity.[24] Macromolecules like proteins and nucleic acids, as well as hydrophilic or hydrophobic tiny medicinal compounds, can be encapsulated by polymeric NPs.[19] nanoparticles that, depending on the situation or time, release the repeated medications through prolixity, swelling, face or bulk corrosion, or prolixity.[20] The most potent cancer treatment nanocarriers might be polymeric nanoparticles. By precisely targeting cancer cells through face-functionalization, these nanoparticles can enhance their therapeutic efficacy and have a longer half-life in the systemic circulation. [21] [22]



Fig 2 . Polymer based drug carriers

Polymeric nanoparticles in cancer treatment

A range of materials, including polymers, dendrimers, liposomes, viruses, carbon nanotubes, and metals like iron oxide and gold, can be utilised to create nanoparticles that are employed to deliver anticancer drugs.[26] There are several ways to accomplish this, including:-

1. Drug uptake by cells by receptor-mediated internalisation or endocytosis.
2. The multidrug resistance proteins can be inhibited by using polymeric materials like Pluronic block copolymers.
3. Raising the drug's concentration in the vicinity of the tumour cell. For a synergistic impact, the inhibitor and medication can both be loaded inside the nanoparticle.[25]

6. Types of Nanoparticles used in drug delivery system

Nanoparticles that work well as medication delivery vehicles These are sub-Micron particles, which range in size from 3 to 200 nm. They can be created utilising a wide range of materials, such as viruses (viral nanoparticles), polymers (polymeric nanoparticles, micelles, or dendrimers), lipids (liposomes), and even organometallic compounds. [27]

6.1 Polymeric carrier

The application of polymeric nanoparticles in the administration of anticancer medications. These are between 10 and 1000 nm in size and are made up of copolymers and polymers. Protecting a drug that is chemically bonded to the surface, adsorbed on it, or enclosed in a particle in an efficient manner. Using polymers to create nanoparticles (NPs) as carriers has significantly improved treatment efficacy by delivering chemotherapeutic drugs to specific areas and minimising negative effects. Polymers can be used alone or in combination with inorganic nanoparticles to form versatile drug delivery systems.[29] Proteins, chitosan, heparin, and other naturally occurring polymers have been used as preferred carriers of medicines, oligonucleotides, DNA, and proteins. Recently, paclitaxel nanoparticles have been made with serum albumin as a carrier. Abraxane is a drug used in clinical settings to treat metastatic breast cancer. It is paclitaxel bound to albumin in a nanometer-sized form.[30]

6.2 Polymeric micelle

Tone-assemblies of copolymers can form the supramolecular structure of polymeric micelles. These are distinct colloidal, globular, and nanoscale patches with distinct core-shell architectures.[31] Polymeric micelles protect the integrated medication from the gastrointestinal tract's environment and release it gradually and precisely at a designated location. They support prolonged systemic rotation and are biocompatible and thermodynamically stable in physiological results. [32]

6.3 Liposomes

Initially described in 1965, liposomes were among the first nanoparticle platforms utilised in drug development.[33] Liposomes are concentric bi-layered vesicles with a membranous lipid bilayer made primarily of synthetic or natural phospholipids enclosing the entire aqueous volume. Liposomes are little spheres composed primarily of phospholipids and other fatty substances.

Liposomes vary in diameter from 50 nm to several micrometres and are composed of one or more concentric lipid bilayers. To increase the stability and rotation half-life of liposomes, carpeting them with polymers similar to polyethylene glycol(cut) is an additional option. Pharmacokinetics are typically improved by liposomal drug compositions.[34]

6.4 Dendrimers

Drug delivery tools at the nanoscale are called dendrimers. Synthetic polymeric macromolecules are used to construct dendrimers, which are composed of many clearly Fanned monomers extending from the central core.[35] One benefit of dendrimers, polymeric nanoparticles, is their adaptability in drug delivery systems.[36] Dendrimers exhibit encouraging properties, including high water solubility, nanoscale size and structure, and the ability to transfer medications via covalent or encapsulation. According to a number of research, dendrimers, cytotoxic, antifungal, and antibacterial qualities limit their effectiveness.[37]

6.5 Carbon nanotubes

In the natural sciences, carbon nanotubes are frequently employed as single-use detectors for tasks including identifying DNA, proteins, and different kinds of proteins from blood samples. They also help in the delivery of proteins and vaccines.[38] Both organic and inorganic nanotubes (such as carbon nanotubes) are possible. Tiny particles arranged in tubes make up carbon nanotubes, which are garbage. For instance, they may have a structure with one or more walls and a final bone.[39]

6.6 Gold nanoparticles

Gold nanoparticles are used in photothermal cancer treatment because of their properties, which include the capacity to be delivered into the original excrescence area while minimising non-specific distribution, the capacity to be actuated by near-infrared (NIR) ray light, which permits access deep into natural apkins, and the capacity to be modulated to produce multifaceted cancer PTT and medication delivery systems.[39]

6.6 viral carrier

Plant contagion nanoparticles, or VNPs, are safe, biodegradable, low-cost to produce, and efficacious as medicinal agents. R factory contagion nanoparticles serve as both cancer therapeutic agents and carriers of vaccine epitopes.[41] Viral structural proteins are used to simulate the antigencity and exterior structure of a genuine virus.

6.7 Nanoshell

Polymeric copolymers with nanoshells ranging from 20 to 60 nm able to come together to form a shell or core. Assembling nanoparticles layer by layer gives rise to a high drug loading efficiency, which is a hallmark of nanoshells.[46] While nanoparticle-based gene therapy techniques mostly focus on spatial control, nanoshells also demonstrate promise as light-triggered gene therapy vectors, providing temporal control.[47]

7. Significance of Nanoparticles in cancer

Delivery vehicles for nanoparticles can contribute in a variety of ways to the activation of weak systems that suppress cancer. It is possible to use nanoparticles to improve T cell activation and antigen donation. When it comes to high stability, high particularity, and high medicine delivery, nanoparticles can provide a substantial advantage over conventional drug administration methods. Carrying weight and regulated abilities. High drug carrying capacity, the ability to administer drugs in a variety of ways, controlled release capabilities, and the potential to distribute both hydrophilic and hydrophobic drugs motes.[48] A completely new age has been ushered in by the use of nanotechnology in cancer diagnosis, therapy, and surgery. NPs combine, either by active or inactive targeting the inside of cells.

The medication release can be controlled and established by designing and modifying the targeted NPs to be either pH-sensitive or temperature-sensitive. A polymeric nanoparticle-based targeted delivery system provides an excellent platform for cancer treatment.[49]

8. Future direction

Despite being a relatively new field of study, clinical care has quickly included nanomedicine. Nanoparticle medicine carriers are well suited for oncology procedures due to their unique packaging. The most severe cancers are being treated with the use of nanoparticle chemotherapeutics. Few clinical trials have been conducted and few nanotherapeutics have been approved for use in clinical settings. Treatment plans are being quickly changed by nanoparticles. New directions have been made possible by the use of enhanced nanoparticle packs in cancer diagnosis and treatment. It is possible to specifically target a medication in parts of the body that conventional macromolecular medications cannot reach by creating passive or active nanostructures. In real-time radiation treatment sessions, the innovative fiber-optical dosimeter (nanoFOD) gadget, for instance, is based on nanomaterials and is used to localise, measure, and quantify the in vivo radiation cure provided during external ray delivery.

9. Conclusion

These new approaches and forms of nanotechnology These days, some of the most cutting-edge methods for cancer therapy are in use. For many years, nanomaterials have been extensively employed in a wide range of scientific, engineering, and technological domains. Nowadays, nanoparticles are frequently employed in biomedical research as a therapeutic approach or as a drug delivery system. Cancer is one of the most difficult diseases for exploratory scientists to treat since it is incurable and causes a wide range of issues and symptoms. Nanotechnology is therefore a crucial drug delivery strategy for improved cancer prevention. The advancement of medication delivery methods based on nanoparticles advances our knowledge of the molecular causes of cancer and how to treat it.

10. Acknowledgement

I am sincerely grateful to my professors, parents for their immense support for publishing the paper.

Reference :-

[1] Shaheen Sultana, Mohd Rashid Khan, Mukesh Kumar, Sokindra Kumar, and Mohammed Ali (2013), Nanoparticle-mediated drug delivery approaches for cancer targeting: a review, Journal of Drug Targeting, 21:2, 107–125, DOI: 10.3109/1061186X.2012.712130.

[2] Frank Alexisa,June-Wha Rheea, Jerome P. Richieb, Aleksandar F. Radovic-Morenoc,Robert Langerc, and Omid C. Farokhzada,New Frontiers in Nanotechnology for Cancer Treatment, Urologic Oncology: Seminars and Original Investigations 26 (2008), 74–85

[3] Bazak R, Houri M, El Achy S, Kamel S, and Refaat T. Cancer active targeting by nanoparticles: a comprehensive review of the literature. J Cancer Res Clin Oncol. 2015 May;141(5):769–84. Doi: 10.1007/s00432-014-1767-3. Epub 2014 Jul 9. PMID: 25005786; PMCID: PMC4710367.

[4] Ali Aghebati-Maleki, Sanam Dolati, Majid Ahmadi, Amir Baghbanzhadeh, Milad Asadi, Ali Fotouhi, Mehdi Yousefi, and Leili Aghebati-Malekli, Nanoparticles and Cancer Therapy: Perspectives for the Application of Nanoparticles in the Treatment of Cancers, Journal of Cellular Physiology, 235 (3), 1962–1972, 2020

[5] Kytai Truong Nguyen, Targeted nanoparticles for cancer therapy: Promises and Challenges, OMICS Group International, 2011.

[6] Jon Zugazagoitia, MD, PhD; Cristiano Guedes, MD; Santiago Ponce, MD; Irene Ferrer, PhD; Sonia Molina-Pinelo, PhD; Luis Paz-Ares, MD, PhD, Current Challenges in Cancer Treatment, Clinical Therapeutics, Volume 38, Issue July 2016, Pages 1551–1566.

[7] Anupam Saini, Manish Kumar, Shailendra Bhatt, Vipin Saini, and Anuj Malik, CANCER CAUSES AND TREATMENTS, IJPSR (2020), Volume 11, Issue

[8] https://www.who.int/news-room/fact-sheets/detail/cancer

[9] Ruth L. Lagman, MD, MPH; Mellar P. Davis, MD, FCCP; Susan B. LeGrand, MD, FACP; Declan Walsh, MSc, FACP, FRCP (Edin) Common Symptoms in Advanced Cancer, Surgical Clinics Volume 85, Issue 2

[10] Charles S. Cleeland, Cancer-related symptoms, Seminars in Radiation Oncology, Volume 10, Issue 3, July 2000, Pages 175–190.

[11] Jones A. (2023) Pathology of Cancer: Causes, Pathophysiology, Diagnosis, Prevention, and Treatment. J Med Surg Pathol. 08:267.

[12] Irène Brigger, Catherine Dubernet, and Patrick Couvreur, Nanoparticles in Cancer Therapy and Diagnosis, Advanced Drug Delivery Reviews, Volume 64, Supplement, December 2012, Pages 24-36.

[13] Awasthi, Rajendra; Roseblade, Ariane; Hansbro, Philip M.; Rathbone, Michael John; Dua, Kamal; Bebawy, Mary, Nanoparticles in Cancer Treatment: Opportunities and Obstacles, Current Drug Targets Volume 19, Number 14, 2018, pp. 1696–1709(14).

[14] Frank Alexis, Eric M. Pridgen, Robert Langer, and Omid C. Farokhzad, Nanoparticle Technologies for Cancer Therapy, Handbook of Experimental Pharmacology, 197

[15] Alexis, F., Pridgen, E.M., Langer, R., and Farokhzad, O.C. (2010). Nanoparticle Technologies for Cancer Therapy. Schäfer-Korting, M. (eds.), Drug Delivery, Handbook of Experimental Pharmacology, vol. 197. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-00477-3_2

[16] Jon Zugazagoitia, MD, PhD; Cristiano Guedes, MD; Santiago Ponce, MD; Irene Ferrer, PhD; Sonia Molina-Pinelo, PhD; Luis Paz-Ares, MD, PhD, Current Challenges in Cancer Treatment, Clinical Therapeutics, Volume 38, Issue 7, July 2016, Pages 1551–1566.

[17] Amit Kumer Biswas et al. (2014) Adv. Nat. Sci: Nanosci. Nanotechnol. 5 043001

[18] Barrera DA, et al. Synthesis and RGD peptide modification of a new biodegradable copolymer: poly(lactic acid-co-lysine) J Am Chem Soc. 1993;115:11010–11011.

[19] Frank X. Gu, Rohit Karnik, Andrew Z. Wang, Frank Alexis, Etgar Levy-Nissenbaum, Seungpyo Hong, Robert S. Langer, and Omid C. Farokhzad, Targeted Nanoparticles for Cancer Therapy, Nanotoday, June 2007, Volume 2, Number 3.

[20] Frank Alexisa, C., June-Wha Rheea, C., Jerome P. Richieb, Aleksandar F. Radovic-Morenoc,Robert Langerc, D., and Omid C. Farokhzad, New Frontiers in Nanotechnology for Cancer Treatment, Urologic Oncology: Seminars and Original Investigations 26 (2008), 74–85

[21] Gref R, Minamitake Y, Peracchia MT, et al. Biodegradable long Circulating polymeric nanospheres. Science 1994;263:1600 –3.

[22] Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-Specific nanoparticles: Theory to practice. Pharmacol Rev 2001;53:283–318.

[23] Zehra Edis, Junli Wang, Muhammad Khurram Waqas, Muhammad Ijaz & Munazza Ijaz (2021) Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives, International Journal of Nanomedicine, , 1313-1330, DOI: 10.2147/IJN.S289443

[24] M.L Hans, A.M Lowman, Biodegradable nanoparticles for drug delivery and targeting, Current Opinion in Solid State and Materials Science, Volume 6, Issue 4,August 2002, Pages 319-327.

[25] Jyoti Ahlawat , Gabriela Henriquez and Mahesh Narayan , Enhancing the Delivery of Chemotherapeutics: Role of Biodegradable Polymeric Nanoparticles ,Molecules 2018, 23, 2157; doi:10.3390/molecules23092157

[26] Chetan C. Anajwala, Girish K. Jani, S.M. Vijayendra SwamySwamy, Current Trends of Nanotechnology for Cancer Therapy, International Journal of Pharmaceutical Sciences and Nanotechnology Volume 3 Issue 3.

[27] Ankita Dadwal, Ashish Baldi & Raj Kumar Narang (2018) Nanoparticles as Carriers for drug delivery in cancer, Artificial Cells, Nanomedicine, and Biotechnology, 46:sup , 295-305 DOI: 10.1080/21691401.2018.1457039

[28] Cheng, Z., Li, M., Dey, R. et al. Nanomaterials for cancer therapy: current progress and perspectives. J Hematol Oncol 14, 85 (2021).

[29] Mohamed Haider , Khaled Zaki Zaki a, Mariam Rafat Hamshary , Zahid Hussain , Gorka Orive , Haidy Osama Ibrahim , Polymeric nanocarriers: A promising tool for early diagnosis and efficient treatment of colorectal cancer, Journal of Advanced Research July 2022, Pages 237-255.

[30] Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of Nanoparticle albumin-bound paclitaxel compared with polyethyLated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794–7803.

[31] Ferrari,M.Cancer nanotechnology: Opportunities and challenges. Nat. Rev. Cancer, 2005, 5, 161-71

[32] Kataoka, K.; Harada, A.; Nagasaki, Y.; Block copolymer micelles For drug delivery: design, characterization and biological signifiCance. Adv. Drug Deliv. Rev, 2001, 43, 113-31

[33] Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2003;2:347–360.

[34] Torchilin VP. Recent advances with liposomes as pharmaceutical Carriers. Nat Rev Drug Discov. 2005;4:145–160.

[35] Zehra Edis, Junli Wang, Muhammad Khurram Waqas, Muhammad Ijaz & Munazza Ijaz (2021) Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives, International Journal of Nanomedicine,1313-1330,DOI: 10.2147/IJN.S289443

[36] Madaan K, Kumar S, Poonia N, Lather V, Pandita D. Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues. J Pharm Bioallied Sci. 2014 Jul;6(3):139-50

[37] Chis AA, Dobrea C, Morgovan C, Arseniu AM, Rus LL, Butuca A, Juncan AM, Totan M, Vonica-Tincu AL, Cormos G, Muntean AC, Muresan ML, Gligor FG, Frum A. Applications and Limitations of Dendrimers in Biomedicine. Molecules. 2020 Sep 1;25(17):3982.

[38] Zhao K, Shi N, Sa Z, Wang HX, Lu CH, Xu XY. Text mining and Analysis of treatise on febrile diseases based on natural language Processing. World J Tradit Chin Med. 2020;6:67–73

[39] Jeremy B. Vines , Jee-Hyun Yoon,Na-Eun Ryu ,Dong-Jin Lim ,Hansoo Park Gold Nanoparticles for Photothermal Cancer Therapy, Sec.Nanoscience Volume 7-2019 | https://doi.org/10.3389/fchem.2019.00167

[40] Srividhya Venkataraman, Paul Apka, Erum Shoeb, Uzma Badar, and Kathleen Hefferon , Plant Virus Nanoparticles for Anti-cancer Therapy, Front Bioeng Biotechnol. 2021; 9: 642794.

[41] Mundekkad, D.; Cho, W.C. Nanoparticles in Clinical Translation For Cancer Therapy. Int. J. Mol. Sci.2022, 23, 1685. https://doi.org/10.3390/ijms23031685

[42] Y. Gazit, J. W. Baish, N. Safabakhsh, M. Leunig, L. T. Baxter, and R. K. Jain, 'Fractal Characteristics of tumor vascular architecture during tumor growth and regression', Microcirculation, 1997.

[43] J. S. Choi and J. S. Park, 'Development of docetaxel nanocrystals surface modified with Transferrin for tumour targeting', Drug Des. Devel. Ther., 2017.

[44] Y. Zhou et al., 'Impact of Single-chain Fv Antibody Fragment Affinity on Nanoparticle Targeting of Epidermal Growth Factor Receptor-expressing Tumour Cells', J. Mol. Biol.,2007.

[45] R. Bhattacharya et al., 'Attaching folic acid on gold nanoparticles using noncovalent Interaction via different polyethylene glycol backbones and targeting of cancer cells',Nanomedicine Nanotechnology, Biol. Med., 2007.

[46] surbhi lal ,Susan E clear, Naomi J halas,nenoshell enabled photothermal cancer therapy : impending clinical impact accounts of chemical research 41(12) ,1842-1851,2008

[47] Rizia bardhan,surbhi lal ,Amit Joshi,Naomi j halas,thermostatic nanoshell: from probe design to imagine and treatment of cancer accounts of chemical research 44(10),936-946,2011

[48] C Karuppusamy, P Venkatesan,1)Role of nanoparticles in drug delivery system: a comprehensive review,Journal of Pharmaceutical sciences and Research 9 (3), 318, 2017

[49] Farha Masood, Polymeric nanoparticles for targeted drug delivery system for cancer therapy, Materials Science and Engineering: C 60, 569-578, 2016 .